#term ID	term description	observed gene count	background gene count	strength	signal	false discovery rate	matching proteins in your network (IDs)	matching proteins in your network (labels)
WP673	ErbB signaling pathway	8	89	1.25	1.17	2.48e-05	9606.ENSP00000233154,9606.ENSP00000265171,9606.ENSP00000293328,9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000384849,9606.ENSP00000469413,9606.ENSP00000500582	NCK2,EGF,STAT5B,CRKL,SRC,CDKN1A,PAK4,AKT3
WP5095	Overview of proinflammatory and profibrotic mediators	8	126	1.1	0.95	0.00015	9606.ENSP00000006053,9606.ENSP00000225474,9606.ENSP00000263851,9606.ENSP00000296026,9606.ENSP00000296027,9606.ENSP00000379110,9606.ENSP00000472467,9606.ENSP00000474412	CX3CL1,CSF3,IL7,CXCL3,CXCL5,CXCL1,CXCL17,CCL5
WP2324	AGE/RAGE pathway	6	66	1.25	0.89	0.00044	9606.ENSP00000293328,9606.ENSP00000311032,9606.ENSP00000356436,9606.ENSP00000362680,9606.ENSP00000405453,9606.ENSP00000479889	STAT5B,CASP3,PLA2G4A,SRC,MSR1,IRAK4
WP5115	Network map of SARS-CoV-2 signaling pathway	9	218	0.91	0.78	0.00044	9606.ENSP00000263851,9606.ENSP00000264498,9606.ENSP00000296026,9606.ENSP00000296027,9606.ENSP00000305769,9606.ENSP00000311032,9606.ENSP00000379110,9606.ENSP00000391592,9606.ENSP00000474412	IL7,FGF2,CXCL3,CXCL5,SMAD1,CASP3,CXCL1,PTPN6,CCL5
WP4205	MET in type 1 papillary renal cell carcinoma	5	58	1.23	0.71	0.0024	9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000384849,9606.ENSP00000469413,9606.ENSP00000500582	CRKL,SRC,CDKN1A,PAK4,AKT3
WP5087	Malignant pleural mesothelioma	11	434	0.7	0.58	0.0024	9606.ENSP00000225474,9606.ENSP00000262320,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000296027,9606.ENSP00000362680,9606.ENSP00000379110,9606.ENSP00000384849,9606.ENSP00000469413,9606.ENSP00000474412,9606.ENSP00000500582	CSF3,AXIN1,FGF2,EGF,CXCL5,SRC,CXCL1,CDKN1A,PAK4,CCL5,AKT3
WP3929	Chemokine signaling pathway	7	165	0.92	0.63	0.0027	9606.ENSP00000006053,9606.ENSP00000293328,9606.ENSP00000296026,9606.ENSP00000296027,9606.ENSP00000346300,9606.ENSP00000474412,9606.ENSP00000500582	CX3CL1,STAT5B,CXCL3,CXCL5,CRKL,CCL5,AKT3
WP4155	Endometrial cancer	5	63	1.19	0.69	0.0027	9606.ENSP00000262320,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000384849,9606.ENSP00000500582	AXIN1,FGF2,EGF,CDKN1A,AKT3
WP437	EGF/EGFR signaling pathway	7	162	0.93	0.64	0.0027	9606.ENSP00000233154,9606.ENSP00000265171,9606.ENSP00000276420,9606.ENSP00000293328,9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000366306	NCK2,EGF,DOK2,STAT5B,CRKL,SRC,SPRY2
WP5039	SARS-CoV-2 innate immunity evasion and cell-specific immune response	5	66	1.17	0.69	0.0027	9606.ENSP00000296026,9606.ENSP00000296027,9606.ENSP00000379110,9606.ENSP00000472467,9606.ENSP00000474412	CXCL3,CXCL5,CXCL1,CXCL17,CCL5
WP4255	Non-small cell lung cancer	5	72	1.14	0.67	0.0031	9606.ENSP00000265171,9606.ENSP00000293328,9606.ENSP00000311032,9606.ENSP00000384849,9606.ENSP00000500582	EGF,STAT5B,CASP3,CDKN1A,AKT3
WP2037	Prolactin signaling pathway	5	76	1.11	0.65	0.0037	9606.ENSP00000293328,9606.ENSP00000300026,9606.ENSP00000311032,9606.ENSP00000362680,9606.ENSP00000391592	STAT5B,PPIB,CASP3,SRC,PTPN6
WP3888	VEGFA-VEGFR2 signaling	10	428	0.66	0.52	0.0045	9606.ENSP00000220764,9606.ENSP00000248553,9606.ENSP00000285735,9606.ENSP00000327801,9606.ENSP00000356436,9606.ENSP00000356505,9606.ENSP00000362680,9606.ENSP00000369081,9606.ENSP00000376367,9606.ENSP00000391592	DECR1,HSPB1,RHOC,P4HB,PLA2G4A,NCF2,SRC,TXNDC5,WASF1,PTPN6
WP286	IL-3 signaling pathway	4	49	1.21	0.58	0.0079	9606.ENSP00000293328,9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000391592	STAT5B,CRKL,SRC,PTPN6
WP4666	Hepatitis B infection	6	150	0.9	0.53	0.0079	9606.ENSP00000293328,9606.ENSP00000311032,9606.ENSP00000362680,9606.ENSP00000384849,9606.ENSP00000479889,9606.ENSP00000500582	STAT5B,CASP3,SRC,CDKN1A,IRAK4,AKT3
WP2864	Apoptosis-related network due to altered Notch3 in ovarian cancer	4	53	1.17	0.55	0.0096	9606.ENSP00000248553,9606.ENSP00000262320,9606.ENSP00000321326,9606.ENSP00000384849	HSPB1,AXIN1,F2R,CDKN1A
WP1539	Angiogenesis	3	23	1.41	0.54	0.0133	9606.ENSP00000264498,9606.ENSP00000305769,9606.ENSP00000362680	FGF2,SMAD1,SRC
WP304	Kit receptor signaling pathway	4	59	1.13	0.51	0.0133	9606.ENSP00000293328,9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000391592	STAT5B,CRKL,SRC,PTPN6
WP3624	Lung fibrosis	4	63	1.1	0.51	0.0133	9606.ENSP00000225474,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000474412	CSF3,FGF2,EGF,CCL5
WP382	MAPK signaling pathway	7	245	0.75	0.46	0.0133	9606.ENSP00000248553,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000311032,9606.ENSP00000346300,9606.ENSP00000356436,9606.ENSP00000500582	HSPB1,FGF2,EGF,CASP3,CRKL,PLA2G4A,AKT3
WP3863	T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection	4	62	1.1	0.51	0.0133	9606.ENSP00000339186,9606.ENSP00000378845,9606.ENSP00000391592,9606.ENSP00000442600	GRAP2,LAT,PTPN6,DAG1
WP3931	Embryonic stem cell pluripotency pathways	5	116	0.93	0.49	0.0133	9606.ENSP00000262320,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000305769,9606.ENSP00000500582	AXIN1,FGF2,EGF,SMAD1,AKT3
WP4172	PI3K-Akt signaling pathway	8	336	0.67	0.44	0.0133	9606.ENSP00000222271,9606.ENSP00000225474,9606.ENSP00000263851,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000321326,9606.ENSP00000384849,9606.ENSP00000500582	COMP,CSF3,IL7,FGF2,EGF,F2R,CDKN1A,AKT3
WP5072	Modulators of TCR signaling and T cell activation	4	61	1.11	0.51	0.0133	9606.ENSP00000339186,9606.ENSP00000345492,9606.ENSP00000378845,9606.ENSP00000391592	GRAP2,SH2B3,LAT,PTPN6
WP530	Cytokines and inflammatory response	3	26	1.36	0.53	0.0133	9606.ENSP00000225474,9606.ENSP00000263851,9606.ENSP00000379110	CSF3,IL7,CXCL1
WP306	Focal adhesion	6	195	0.78	0.44	0.0165	9606.ENSP00000222271,9606.ENSP00000265171,9606.ENSP00000346300,9606.ENSP00000362680,9606.ENSP00000469413,9606.ENSP00000500582	COMP,EGF,CRKL,SRC,PAK4,AKT3
WP4216	Chromosomal and microsatellite instability in colorectal cancer 	4	72	1.04	0.48	0.0172	9606.ENSP00000262320,9606.ENSP00000311032,9606.ENSP00000384849,9606.ENSP00000500582	AXIN1,CASP3,CDKN1A,AKT3
WP2261	Glioblastoma signaling pathways	4	82	0.98	0.43	0.0259	9606.ENSP00000362680,9606.ENSP00000366306,9606.ENSP00000384849,9606.ENSP00000500582	SRC,SPRY2,CDKN1A,AKT3
WP2380	Brain-derived neurotrophic factor (BDNF) signaling pathway	5	143	0.84	0.41	0.0259	9606.ENSP00000233154,9606.ENSP00000293328,9606.ENSP00000311032,9606.ENSP00000356505,9606.ENSP00000362680	NCK2,STAT5B,CASP3,NCF2,SRC
WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway	7	301	0.66	0.38	0.0259	9606.ENSP00000222271,9606.ENSP00000225474,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000321326,9606.ENSP00000384849,9606.ENSP00000500582	COMP,CSF3,FGF2,EGF,F2R,CDKN1A,AKT3
WP4806	EGFR tyrosine kinase inhibitor resistance	4	83	0.98	0.43	0.0259	9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000362680,9606.ENSP00000500582	FGF2,EGF,SRC,AKT3
WP2371	Parkinsons disease pathway	3	38	1.19	0.44	0.0263	9606.ENSP00000258080,9606.ENSP00000311032,9606.ENSP00000312664	HTRA2,CASP3,CASP2
WP2828	Bladder cancer	3	39	1.18	0.44	0.0263	9606.ENSP00000265171,9606.ENSP00000362680,9606.ENSP00000384849	EGF,SRC,CDKN1A
WP4262	Breast cancer pathway	5	154	0.81	0.4	0.0263	9606.ENSP00000262320,9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000384849,9606.ENSP00000500582	AXIN1,FGF2,EGF,CDKN1A,AKT3
WP4263	Pancreatic adenocarcinoma pathway	4	86	0.96	0.42	0.0263	9606.ENSP00000265171,9606.ENSP00000384849,9606.ENSP00000469413,9606.ENSP00000500582	EGF,CDKN1A,PAK4,AKT3
WP4298	Acute viral myocarditis	4	85	0.97	0.42	0.0263	9606.ENSP00000311032,9606.ENSP00000312664,9606.ENSP00000362680,9606.ENSP00000442600	CASP3,CASP2,SRC,DAG1
WP51	Regulation of actin cytoskeleton	5	149	0.82	0.41	0.0263	9606.ENSP00000264498,9606.ENSP00000265171,9606.ENSP00000321326,9606.ENSP00000376367,9606.ENSP00000469413	FGF2,EGF,F2R,WASF1,PAK4
WP5285	Immune infiltration in pancreatic cancer	3	38	1.19	0.44	0.0263	9606.ENSP00000296027,9606.ENSP00000379110,9606.ENSP00000474412	CXCL5,CXCL1,CCL5
WP3937	Microglia pathogen phagocytosis pathway	3	40	1.17	0.44	0.0264	9606.ENSP00000356505,9606.ENSP00000378845,9606.ENSP00000391592	NCF2,LAT,PTPN6
WP69	T-cell receptor signaling pathway	4	90	0.94	0.42	0.0264	9606.ENSP00000339186,9606.ENSP00000345492,9606.ENSP00000346300,9606.ENSP00000378845	GRAP2,SH2B3,CRKL,LAT
WP4746	Thyroid hormones production and peripheral downstream signaling effects	4	93	0.93	0.41	0.0282	9606.ENSP00000013125,9606.ENSP00000265052,9606.ENSP00000362680,9606.ENSP00000500582	MAP4K5,MGLL,SRC,AKT3
WP4136	Fibrin complement receptor 3 signaling pathway	3	43	1.14	0.42	0.0301	9606.ENSP00000296026,9606.ENSP00000362680,9606.ENSP00000479889	CXCL3,SRC,IRAK4
WP4534	Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms	3	45	1.12	0.41	0.0333	9606.ENSP00000013125,9606.ENSP00000362680,9606.ENSP00000469413	MAP4K5,SRC,PAK4
WP2203	Thymic stromal lymphopoietin (TSLP) signaling pathway	3	47	1.1	0.4	0.0366	9606.ENSP00000293328,9606.ENSP00000362680,9606.ENSP00000462468	STAT5B,SRC,YES1
WP4747	Netrin-UNC5B signaling pathway	3	52	1.06	0.37	0.0471	9606.ENSP00000311032,9606.ENSP00000362680,9606.ENSP00000380942	CASP3,SRC,ARHGEF12
WP5144	NRP1-triggered signaling pathways in pancreatic cancer 	3	52	1.06	0.37	0.0471	9606.ENSP00000265171,9606.ENSP00000362680,9606.ENSP00000500582	EGF,SRC,AKT3
WP395	IL-4 signaling pathway	3	54	1.04	0.36	0.0488	9606.ENSP00000276420,9606.ENSP00000293328,9606.ENSP00000391592	DOK2,STAT5B,PTPN6
WP4659	Gastrin signaling pathway	4	113	0.84	0.35	0.0488	9606.ENSP00000311032,9606.ENSP00000362680,9606.ENSP00000384849,9606.ENSP00000462468	CASP3,SRC,CDKN1A,YES1
